Pulmonary Fibrosis - Pipeline Review, H1 2016

Description: Pulmonary Fibrosis - Pipeline Review, H1 2016

Summary

‘Pulmonary Fibrosis - Pipeline Review, H1 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pulmonary Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Fibrosis and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pulmonary Fibrosis
- The report reviews pipeline therapeutics for Pulmonary Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Pulmonary Fibrosis therapeutics and enlists all their major and minor projects
- The report assesses Pulmonary Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Pulmonary Fibrosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Fibrosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

List of Tables
List of Figures
Introduction
Report Coverage
Pulmonary Fibrosis Overview
Therapeutics Development
Pipeline Products for Pulmonary Fibrosis - Overview
Pipeline Products for Pulmonary Fibrosis - Comparative Analysis
Pulmonary Fibrosis - Therapeutics under Development by Companies
Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes
Pulmonary Fibrosis - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Pulmonary Fibrosis - Products under Development by Companies
Pulmonary Fibrosis - Products under Investigation by Universities/Institutes
Pulmonary Fibrosis - Companies Involved in Therapeutics Development
AdAlta Pty Ltd.
Advinus Therapeutics Ltd.
Aeolus Pharmaceuticals, Inc.
Afferent Pharmaceuticals, Inc.
AnaMar AB
Angion Biomedica Corp.
Antitope Limited
aTyr Pharma, Inc.
Biogen, Inc.
Bioneer Corporation
BiOrion Technologies B.V.
Bristol-Myers Squibb Company
Carolus Therapeutics, Inc.
Celgene Corporation
Chong Kun Dang Pharmaceutical Corp.
Clanotech AB
Compugen Ltd.
Cynata Therapeutics Limited
Diffusion Pharmaceuticals Inc.
Digna Biotech, S.L.
Elsalys Biotech SAS
F. Hoffmann-La Roche Ltd.
FibroGen, Inc.
Galapagos NV
Galectin Therapeutics, Inc.
GenKyoTex S.A.
GlaxoSmithKline Plc
Global Blood Therapeutics, Inc.
HanAll Biopharma Co., Ltd.
HEC Pharm Co., Ltd.
Histocell S.L.
Hydra Biosciences, Inc.
iBio, Inc.
Inventiva
Isarna Therapeutics GmbH
Kadmon Corporation, LLC
Kasiak Research Private Limited
KineMed, Inc.
Kyorin Pharmaceutical Co., Ltd.
Lpath, Inc.
miRagen Therapeutics, Inc.
Moerae Matrix, Inc.
MorphoSys AG
NicOx S.A.
Novartis AG
Pacific Therapeutics Ltd.
Pharmaxis Limited
Pharmicell Co., Ltd.
Pluristem Therapeutics Inc.
Progenra, Inc.
Promedior, Inc.
ProMetic Life Sciences Inc.
Pulmatrix, Inc.
RedHill Biopharma Ltd.
Respira Therapeutics, Inc.
Rhizen Pharmaceuticals S.A.
Ribomic Inc.
Saje Pharma, LLC
Sanofi
SciFluor Life Sciences, LLC
Symic Biomedical, Inc.
TaiwanJ Pharmaceuticals Co., Ltd.
Teva Pharmaceutical Industries Limited
Therabron Therapeutics, Inc.
Vericel Corporation
Yuhan Corporation
Pulmonary Fibrosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(acetylcysteine + pentoxifylline) - Drug Profile
ABC-294640 - Drug Profile
acALY-18 - Drug Profile
AEOL-10150 - Drug Profile
AF-219 - Drug Profile
Altepan - Drug Profile
AM-0010 - Drug Profile
AMAP-102 - Drug Profile
Antibodies to Inhibit LPA1 for Idiopathic Pulmonary Fibrosis - Drug Profile
Antisense RNAi Oligonucleotide for COPD and IPF - Drug Profile
BB-3 - Drug Profile
BG-00011 - Drug Profile
BMS-986020 - Drug Profile
BOT-191 - Drug Profile
CC-539 - Drug Profile
CC-90001 - Drug Profile
Cellgram-Lung - Drug Profile
CG-1011 - Drug Profile
CGEN-25009 - Drug Profile
CKD-942 - Drug Profile
CLT-28643 - Drug Profile
CM-101 - Drug Profile
CMYJH-01 - Drug Profile
CT-140 - Drug Profile
CT-2009 - Drug Profile
D-9030 - Drug Profile
DB-02901 - Drug Profile
disitertide - Drug Profile
Drug to Inhibit Galectin-3 for Fibrosis - Drug Profile
Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile
FG-3019 - Drug Profile
GBT-1118 - Drug Profile
GBT-440 - Drug Profile
GKT-831 - Drug Profile
GLPG-1690 - Drug Profile
GRMD-02 - Drug Profile
GSK-3008348 - Drug Profile
HC-067047 - Drug Profile
HEC-00000585 - Drug Profile
HL-156FIB - Drug Profile
HR-017 - Drug Profile
IBIOCFB-03 - Drug Profile
ICG-001 - Drug Profile
iMod.Fc - Drug Profile
ISTH-0047 - Drug Profile
ITMN-10534 - Drug Profile
ITMN-14440 - Drug Profile
ITMN-30162 - Drug Profile
IVA-337 - Drug Profile
ixmyelocel-T - Drug Profile
JKB-117 - Drug Profile
JKB-119 - Drug Profile
KBP-7018 - Drug Profile
KD-025 - Drug Profile
lebrikizumab - Drug Profile
Lpathomab - Drug Profile
LT-0011 - Drug Profile
LTI-03 - Drug Profile
MGN-4220 - Drug Profile
MMI-0100 - Drug Profile
Monoclonal Antibodies to Inhibit S100-B for Idiopathic Pulmonary Fibrosis and COPD - Drug Profile
MOR-107 - Drug Profile
NAS-911 - Drug Profile
NCX-466 - Drug Profile
Neumomir - Drug Profile
noscapine - Drug Profile
Oligonucleotides for Respiratory and Oncology - Drug Profile
OLX-201 - Drug Profile
omipalisib - Drug Profile
P-007 - Drug Profile
P-013 - Drug Profile
PB-01 - Drug Profile
PBF-1129 - Drug Profile
PBI-4050 - Drug Profile
PBI-4425 - Drug Profile
Peptide to Target C/EBP-Beta for Lung Fibrosis - Drug Profile
pirfenidone - Drug Profile
PLX-PAD - Drug Profile
PNQ-103 - Drug Profile
PRI-724 - Drug Profile
PRM-151 - Drug Profile
PUR-1500 - Drug Profile
PXS-4820 - Drug Profile
Q-122 - Drug Profile
RBM-005 - Drug Profile
RBM-006 - Drug Profile
Recombinant MMP-9 Replacement for Liver Fibrosis, Pulmonary Fibrosis, Dupuytren Contracture, Peyronies Disease and Transplantation - Drug Profile
Recombinant Peptides for Fibrosis - Drug Profile
Recombinant Protein for Inflammation and Pulmonary Fibrosis - Drug Profile
Refacell-IPF - Drug Profile
RES-529 - Drug Profile
RP-3128 - Drug Profile
RP-6503 - Drug Profile
RT-234 - Drug Profile
SAR-156597 - Drug Profile
SB-300 - Drug Profile
SD-560 - Drug Profile
SM-04646 - Drug Profile
Small Molecule for Idiopathic Pulmonary Fibrosis - Drug Profile
Small Molecule to Antagonize AlphaVBetal for Fibrosis - Drug Profile
Small Molecule to Inhibit MAPK for Pulmonary Fibrosis - Drug Profile
Small Molecules for COPD and IPF - Drug Profile
Small Molecules for Fibrosis - Drug Profile
Small Molecules for Liver Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile
Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile
Small Molecules to Antagonize Integrin Alpha V for Idiopathic Pulmonary Fibrosis - Drug Profile
Small Molecules to Antagonize Integrins for Idiopathic Pulmonary Fibrosis - Drug Profile
Small Molecules to Antagonize LPA1 Receptor for Pulmonary Fibrosis - Drug Profile
Small Molecules to Inhibit Autotaxin for Lung Cancer and Idiopathic Pulmonary Fibrosis - Drug Profile
Small Molecules to Inhibit LOXL2 for Idiopathic Pulmonary Fibrosis - Drug Profile
Small Molecules to Inhibit PTPN13 for Idiopathic Pulmonary Fibrosis - Drug Profile
Small Molecules to Inhibit USP34 for Idiopathic Pulmonary Fibrosis - Drug Profile
SPL-334 - Drug Profile
Stem Cell Therapy for Idiopathic Lung Fibrosis - Drug Profile
Stem Cell Therapy for Idiopathic Pulmonary Fibrosis - Drug Profile
Stem Cell Therapy for Lung Fibrosis - Drug Profile
Synthetic Peptide to Antagonize CD168 for Respiratory, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile
Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile
Synthetic Peptides to Inhibit PDE-4A4 for Pulmonary Fibrosis and Nerve Injury - Drug Profile
TD-139 - Drug Profile
tipelukast - Drug Profile
TM-5441 - Drug Profile
vismodegib - Drug Profile
YH-siRNA1 - Drug Profile
ZL-2102 - Drug Profile
Products under Development by Companies, H1 2016 (Contd.,6)

Products under Investigation by Universities/Institutes, H1 2016

Pulmonary Fibrosis - Pipeline by AdAlta Pty Ltd., H1 2016

Pulmonary Fibrosis - Pipeline by Advinus Therapeutics Ltd., H1 2016

Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by Afferent Pharmaceuticals, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by AnaMar AB, H1 2016

Pulmonary Fibrosis - Pipeline by Angion Biomedica Corp., H1 2016

Pulmonary Fibrosis - Pipeline by Antitope Limited, H1 2016

Pulmonary Fibrosis - Pipeline by aTyr Pharma, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by Biogen, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by Bioneer Corporation, H1 2016

Pulmonary Fibrosis - Pipeline by BiOrion Technologies B.V., H1 2016

Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Company, H1 2016

Pulmonary Fibrosis - Pipeline by Carolus Therapeutics, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by Celgene Corporation, H1 2016

Pulmonary Fibrosis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016

Pulmonary Fibrosis - Pipeline by Clanotech AB, H1 2016

Pulmonary Fibrosis - Pipeline by Compugen Ltd., H1 2016

Pulmonary Fibrosis - Pipeline by Cynata Therapeutics Limited, H1 2016

Pulmonary Fibrosis - Pipeline by Diffusion Pharmaceuticals Inc., H1 2016

Pulmonary Fibrosis - Pipeline by Digna Biotech, S.L., H1 2016

Pulmonary Fibrosis - Pipeline by Elsalys Biotech SAS, H1 2016

Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Pulmonary Fibrosis - Pipeline by FibroGen, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by Galapagos NV, H1 2016

Pulmonary Fibrosis - Pipeline by Galectin Therapeutics, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by GenKyoTex S.A., H1 2016

Pulmonary Fibrosis - Pipeline by GlaxoSmithKline Plc, H1 2016

Pulmonary Fibrosis - Pipeline by Global Blood Therapeutics, Inc., H1 2016

Pulmonary Fibrosis - Pipeline by HanAll Biopharma Co., Ltd., H1 2016

Pulmonary Fibrosis - Pipeline by HEC Pharm Co., Ltd., H1 2016
Number of Products by Stage and Top 10 Routes of Administration, H1 2016
Number of Products by Top 10 Molecule Types, H1 2016
Number of Products by Stage and Top 10 Molecule Types, H1 2016

Ordering:

Order Online - [http://www.researchandmarkets.com/reports/3714987/](http://www.researchandmarkets.com/reports/3714987/)
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Pulmonary Fibrosis - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3714987/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td>□</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Single User:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td>□</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Site License:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td>□</td>
<td>USD 6000</td>
</tr>
<tr>
<td>EnterpriseWide:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  Mr □  Mrs □  Dr □  Miss □  Ms □  Prof □
First Name: ___________________________________________ Last Name: _____________________________
Email Address: * _______________________________________
Job Title: ____________________________________________
Organisation: _________________________________________
Address: _____________________________________________
City: _____________________________________________
Postal / Zip Code: __________________________________
Country: ___________________________________________
Phone Number: _______________________________________
Fax Number: _________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World